Of 510 patients with NSCLC, 50 (9.8%) had MUC16 variant tumors and, compared with patients with MUC16 wild-type tumors, had higher median (interquartile range) tumor variant burden (8.3 [7.5-9.3] vs 3.2 [2.3-4.4]; P < .001) and longer PFS (HR, 0.42; 95% CI, 0.28-0.64; P < .001) (Figure 2A) and OS (HR, 0.38; 95% CI, 0.17-0.86; P = .02) (Figure 2B). This evidence concerns the gene MUC16 and neoplasm.